Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We herein report a case of the beneficial effect of osimertinib readministration in non-small-cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. A 69-year-old non-smoking woman was diagnosed with advanced NSCLC harboring an EGFR exon19 deletion and T790M. She was treated with osimertinib for two years but eventually acquired resistance. After 1.5 years of salvage chemotherapies, osimertinib was re-administered. She has been effectively and safely treated with osimertinib readministration for over 10 months. A prospective study is warranted to evaluate the efficacy and safety of osimertinib readministration in NSCLC with EGFR mutations.

Original languageEnglish
Pages (from-to)1625-1627
Number of pages3
JournalInternal medicine (Tokyo, Japan)
Volume58
Issue number11
DOIs
Publication statusPublished - Jun 1 2019

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
osimertinib
Prospective Studies
Safety
Drug Therapy

Keywords

  • EGFR T790M
  • non-small cell lung cancer
  • osimertinib
  • readministration

ASJC Scopus subject areas

  • Internal Medicine

Cite this

@article{f3ee995080004001bbdfee2cec3686e8,
title = "Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib",
abstract = "We herein report a case of the beneficial effect of osimertinib readministration in non-small-cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. A 69-year-old non-smoking woman was diagnosed with advanced NSCLC harboring an EGFR exon19 deletion and T790M. She was treated with osimertinib for two years but eventually acquired resistance. After 1.5 years of salvage chemotherapies, osimertinib was re-administered. She has been effectively and safely treated with osimertinib readministration for over 10 months. A prospective study is warranted to evaluate the efficacy and safety of osimertinib readministration in NSCLC with EGFR mutations.",
keywords = "EGFR T790M, non-small cell lung cancer, osimertinib, readministration",
author = "Go Makimoto and Kadoaki Oohashi and Satoru Senoo and Katsuyuki Hotta and Yoshinobu Maeda and Katsuyuki Kiura",
year = "2019",
month = "6",
day = "1",
doi = "10.2169/internalmedicine.2152-18",
language = "English",
volume = "58",
pages = "1625--1627",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "11",

}

TY - JOUR

T1 - Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib

AU - Makimoto, Go

AU - Oohashi, Kadoaki

AU - Senoo, Satoru

AU - Hotta, Katsuyuki

AU - Maeda, Yoshinobu

AU - Kiura, Katsuyuki

PY - 2019/6/1

Y1 - 2019/6/1

N2 - We herein report a case of the beneficial effect of osimertinib readministration in non-small-cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. A 69-year-old non-smoking woman was diagnosed with advanced NSCLC harboring an EGFR exon19 deletion and T790M. She was treated with osimertinib for two years but eventually acquired resistance. After 1.5 years of salvage chemotherapies, osimertinib was re-administered. She has been effectively and safely treated with osimertinib readministration for over 10 months. A prospective study is warranted to evaluate the efficacy and safety of osimertinib readministration in NSCLC with EGFR mutations.

AB - We herein report a case of the beneficial effect of osimertinib readministration in non-small-cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. A 69-year-old non-smoking woman was diagnosed with advanced NSCLC harboring an EGFR exon19 deletion and T790M. She was treated with osimertinib for two years but eventually acquired resistance. After 1.5 years of salvage chemotherapies, osimertinib was re-administered. She has been effectively and safely treated with osimertinib readministration for over 10 months. A prospective study is warranted to evaluate the efficacy and safety of osimertinib readministration in NSCLC with EGFR mutations.

KW - EGFR T790M

KW - non-small cell lung cancer

KW - osimertinib

KW - readministration

UR - http://www.scopus.com/inward/record.url?scp=85064245350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064245350&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.2152-18

DO - 10.2169/internalmedicine.2152-18

M3 - Article

C2 - 30713295

AN - SCOPUS:85064245350

VL - 58

SP - 1625

EP - 1627

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 11

ER -